- Home
- AMLX
as 07-11-2025 4:00pm EST
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 459.1M | IPO Year: | 2022 |
| Target Price: | $11.00 | AVG Volume (30 days): | 2.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.76 - $7.72 | Next Earning Date: | 08-07-2025 |
| Revenue: | N/A | Revenue Growth: | -77.06% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Amylyx Pharmaceuticals Inc. News
AMLX Breaking Stock News: Dive into AMLX Ticker-Specific Updates for Smart Investing
Motley Fool
15 days ago
Why Shares in Amylyx Pharmaceuticals Soared This Week
Insider Monkey
18 days ago
Amylyx Pharmaceuticals Gains FDA Fast Track for ALS Drug AMX0114
MT Newswires
18 days ago
Guggenheim Initiates Amylyx Pharmaceuticals at Buy With $17 Price Target
MT Newswires
a month ago
Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday
MT Newswires
a month ago
Amylyx Pharmaceuticals' Potential ALS Treatment Gets FDA Fast Track Designation
Business Wire
a month ago
Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis
MT Newswires
a month ago
TD Cowen Initiates Coverage on Amylyx Pharmaceuticals With Buy Rating
Business Wire
2 months ago
Amylyx Pharmaceuticals to Participate in Upcoming June Investor Conferences
Compare AMLX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AMLX Amylyx Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.